NCT00678106已完成1 期
A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Dalbavancin In Hospitalized Adolescents, Aged 12 Through 17 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Pharmacokinetic Plasma - Cmax, Tmax, AUClast, AUCinf, AUC(48) (as data permit), t1/2 (as data permit), CL, Vss. Urine - Ae48, Ae48% and CLR.
研究概览
简要总结
Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at different time points. Safety labs will also be checked on a regular basis to assess the safety of dalbavancin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •12 to 17 year old adolescents hospitalized for the treatment of bacterial infections.
排除标准
- •Patients being treated with vancomycin.
- •Patients with liver and kidney failure.
- •Pregnant female subjects.
研究组 & 干预措施
1
Experimental
干预措施: Dalbavancin (Drug)
结局指标
主要结局
Pharmacokinetic Plasma - Cmax, Tmax, AUClast, AUCinf, AUC(48) (as data permit), t1/2 (as data permit), CL, Vss. Urine - Ae48, Ae48% and CLR.
时间窗: 56 days
次要结局
- Safety assessments: adverse event monitoring; clinical laboratory tests (hematology, serum chemistry, and urinalysis); ECGs; blood pressure and pulse rate determinations; weight and physical examination.(56 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionHepatic ImpairmentNCT01631097AVEO Pharmaceuticals, Inc.44
已完成
1 期
Desidustat in the Treatment of Chemotherapy Induced AnemiaAnemia of Chronic Kidney DiseaseChemotherapy EffectNCT04667533Zydus Lifesciences Limited24
已完成
1 期
A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy ParticipantsHepatic InsufficiencyNCT03341884Genentech, Inc.29
终止
1 期
Study of Uptake, Break Down and Elimination of an Investigational Drug in Healthy VolunteersAlzheimer's DiseaseNCT00777361AstraZeneca9
终止
1 期
Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal InsufficiencyRenal Insufficiency, AcuteRenal Insufficiency, ChronicHealthy SubjectsNCT02808052Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)9